Non-small-cell lung carcinoma (NSCLC) is often fatal because most cases are not diagnosed until they are so advanced that surgical intervention is no longer possible. To improve outcomes researchers ...

According to recent research published in the Journal of Molecular Diagnostics, outcomes of patients with non-small-cell lung carcinoma (NSCLC) may be improved due to novel technology that is ...

To improve outcomes for patients with non-small-cell lung carcinoma researchers are developing a blood test to detect lung cancer earlier in the disease. A report describes a new technology, electric ...

Finger-prick blood testing has been facing a lot of criticism as of late due to variations in measurements and possible unethical business practices. However, thanks to technology developed by ...

The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past 10 years. Although tumor tissue biopsy-based genotyping is the ...

Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I.

In non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) mutations have emerged as important biomarkers in predicting the response to the EGFR tyrosine kinase inhibitors. The ...

Genomic profiling and targeted therapy in cholangiocarcinoma to yield positive clinical outcomes. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does not include a ...

Philadelphia, October 8, 2018 - Non-small-cell lung carcinoma (NSCLC) is often fatal because most cases are not diagnosed until they are so advanced that surgical intervention is no longer possible.

Non-small-cell lung carcinoma (NSCLC) is often fatal because most cases are not diagnosed until they are so advanced that surgical intervention is no longer possible. To improve outcomes researchers ...